DOCSLIB.ORG

Vasopressin in Chronic Kidney Disease: an Elephant in the Room?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vasopressin in Chronic Kidney Disease: an Elephant in the Room? View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector http://www.kidney-international.org commentary © 2009 International Society of Nephrology see original article on page 960 proteinuria, renal hypertrophy, glomeru- Vasopressin in chronic kidney losclerosis, and tubulointerstitial fi brosis in 5 / 6 nephrectomized rats.6,7 Compensa- disease: an elephant in the room? tory renal hypertrophy and CKD progres- sion following 5 / 6 nephrectomy are 1 Vicente E. Torres attenuated in Brattleboro rats, which can- not secrete AVP, although a study of Perico et al. report that a dual arginine vasopressin (AVP) V2 and V1a shorter duration (3 versus 13 weeks) did receptor antagonist lowers blood pressure, proteinuria, and not detect this eff ect. 8,9 Brattleboro rats glomerulosclerosis in 5 / 6 nephrectomized rats, pointing to its potential with diabetes mellitus exhibit no or mark- value in the treatment of chronic kidney disease (CKD). AVP likely edly reduced glomerular hyperfi ltration, contributes to CKD progression by its effects on renal hemodynamics, albuminuria, and renal hypertrophy com- pared with wild-type controls.4 These blood pressure, and mesangial and/ or epithelial cells, but the relative observations seem to contradict a post hoc contributions of V2 and V1a receptors and potential usefulness of V2 and analysis of the Modification of Diet in V1a receptor antagonists remain ill defined. Renal Disease (MDRD) study in which an Kidney International (2009) 76, 925 – 928. doi: 10.1038/ki.2009.325 association between high urine volumes and rates of GFR decline was thought to refl ect a deleterious eff ect of increased In this issue of Kidney International , increases in single-nephron perfusion, water intake on disease progression. 10 Perico et al.1 report that treatment with glomerular capillary hydraulic pressure, However, it is impossible to conclude from RWJ-676070, a dual V1a and V2 arginine and filtration rate; resetting of tubu- this analysis whether high urine fl ow rate vasopressin receptor antagonist (V1 / loglomerular feedback, allowing persist- was a cause or a consequence of GFR V2 RA), initiated 3 weeks after 5 / 6 ent glomerular hyperfi ltration; and failure decline, or whether another independent nephrectomy, signifi cantly lowers blood of autoregulation, exposing glomerular factor infl uenced the two variables simul- pressure, proteinuria, and glomeruloscle- capillaries to systemic hypertension . Th e taneously. Furthermore, this association rosis in rats. Combined treatment with superiority of ACEIs and ARBs in treating is not unexpected, since defective urine- RWJ-676070 and an angiotensin-convert- glomerular capillary hypertension, as concentrating capacity is a manifestation ing enzyme inhibitor (ACEI) or an angi- compared with antihypertensive agents of CKD. In the study by Perico et al. , 1 otensin II type 1 receptor blocker (ARB) that mainly dilate preglomerular vessels urine output more than doubled in the 5 / 6 has eff ects on proteinuria, renal function, or activate the renin – angiotensin system, nephrectomized as compared with the and structure that are numerically, but not has established the central role of angi- control rats and did not increase further significantly, greater than those of an otensin II in this pathway. In addition, following V 1a / V 2 RA administration, pos- ACEI or an ARB alone. Th e authors sug- angiotensin II exerts non-hemodynamic sibly because of AVP-resistant downregu- gest that non-peptide arginine vasopressin effects on vascular smooth muscle, lation of aquaporin-2 and -3, as well as (AVP) receptor antagonists could be reno- endothelial and mesangial cells, podo- downregulation of aquaporin-1. 11 protective in patients with proteinuric cytes, and tubular epithelial and intersti- Like angiotensin II, AVP has eff ects on chronic kidney disease (CKD). tial cells that contribute to CKD glomerular hemodynamics, arterial Th e identifi cation of a common path- progression. blood pressure, and non-hemodynamic way of progressive renal damage, regard- Although under-recognized, a large renal mechanisms. AVP acts on three G less of the initiating injury, achieved by body of evidence suggests that AVP con- protein-coupled receptors: V2 (cyclic research in animal models of nondiabetic tributes to nondiabetic and diabetic CKD adenosine monophosphate (cAMP ) sec- CKD (5 / 6 nephrectomy) and diabetic progression. Plasma AVP levels are ond messenger) and V1a and V1b (also CKD (streptozotocin-induced diabetes increased in animal models and patients called V 3 ) (calcium second messenger). mellitus) has been one of the major with nondiabetic CKD, in animal models In the kidney, V 2 receptors are found in achievements in nephrology. 2 Th is path- of streptozotocin-induced and genetic the medullary thick ascending limb of way includes reductions in aff erent and, diabetes mellitus, and in patients with Henle (TAL), macula densa, connecting to a lesser degree, eff erent arteriolar tone; type 1 and type 2 diabetes mellitus. 3,4 tubule, and cortical and medullary col- Plasma levels of copeptin, a surrogate lecting ducts, and to a lesser extent in 1 Mayo Clinic College of Medicine , Rochester , MN , marker derived from the C-terminal por- the cortical TAL and distal convoluted U S A tion of the AVP precursor, are inversely tubule (Figure 1 ). 12 Contrary to previ- Correspondence: Vicente E. Torres, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, correlated with glomerular fi ltration rate ous belief, a recent comparative study 5 Minnesota 55905, USA. (GFR). Suppression of AVP by increasing has shown similar patterns of V2 recep- E-mail: [email protected] water ingestion reduces blood pressure, tor expression in the rat, mouse, and Kidney International (2009) 76 925 commentary Filtered plus recycled urea CNT CNT CNT CCD C CCD C CCD Filtered C M DCT DCT urea M DCT aa aa aa ILA MD ILA MD ILA MD ea CTAL ea CTAL ea CTAL AVR OS AVR OS AVR OS AA DVR AA DVR AA DVR MTAL IS MTAL IS MTAL IS UT-B IM IM IM MCD MCD MCD UT-A2 Strong intensity Intermediate intensity UT-B UT-A1/A3 Low intensity Positive signal No signal Recycled Positive α-intercalated cells Positive α-intercalated cells urea Urea excretion Figure 1 | Mechanisms of vasopressin effects on the kidney. ( a ) Segmental distribution of AVP V1a receptor. AVP, acting on V1a receptors in the macula densa, regulates renin secretion; acting on V1a receptors in the vasa recta, it reduces blood flow to the inner medulla and minimizes solute escape from the medullary interstitium; and acting on V1a receptors on the luminal side of collecting-duct principal cells, it stimulates synthesis of prostaglandins that attenuate V2 -mediated antidiuretic action and inhibit sodium transport. (Adapted from refs. 13, 14, and 31 .) (b ) Segmental distribution of AVP V 2 receptor. AVP, acting on V2 receptors, contributes to urinary concentration by inserting aquaporin-2 (AQP-2) into the apical cell membrane of collecting-duct principal cells within minutes and upregulating AQP-2 gene expression in the longer term; activating UT-A1 and UT-A3 in the terminal part of the inner medullary collecting duct; stimulating epithelial sodium channel (ENaC) sodium transport in cortical and outer medullary collecting ducts; and increasing NaK2Cl cotransporter expression and sodium reabsorption in the thick ascending limb of the loop of Henle. (Adapted from ref. 12.) ( c ) Vascular and tubular routes of urea recycling within the kidney. Only a long loop of Henle is depicted, for simplicity. Urea delivery to the inner medulla and transit in ascending vasa recta are shown in green. The pathways allowing urea to return to the inner medulla are indicated by red arrows for the vascular route and by blue arrows for the tubular route. (Adapted from ref. 38) AA, arcuate artery; aa, afferent arteriole; AVR, ascending vasa recta; C, cortex; CCD, cortical collecting duct; CNT, connecting tubule; CTAL, cortical thick ascending limb of Henle; DCT, distal convoluted tubule; DVR, descending vasa recta; ea, efferent arteriole; ILA, interlobular artery; IM, inner medulla; IS, inner stripe of the outer medulla; M, mesangium; MCD, medullary collecting duct; MD, macula densa; MTAL, medullary thick ascending limb of Henle; OS, outer stripe of the outer medulla; UT-A1 / A3, vasopressin-regulated urea transporters A1 / A3; UT-A2, urea transporter A2; UT-B, urea transporter B. human TAL and collecting duct, and of receptor agonist 1-deamino-8 -D- arginine probably due to suppression of tubu- AVP-dependent NaK2Cl cotransporter AVP (DDAVP), but not AVP, worsens loglomerular feedback, possibly caused phosphorylation in TAL cells from rats proteinuria and renal insuffi ciency in 5 / 6 by enhanced urea recycling and / or 12 and rabbits. V1a receptors are found in nephrectomized Brattleboro rats even sodium chloride reabsorption in the TAL, the renal vasculature from the interlob- raised the possibility that V 1a eff ects of lowering the sodium concentration at the ular arteries to the eff erent arterioles AVP could afford a relative protection macula densa. Th ese eff ects, which are and vasa recta, mesangial cells, macula against deleterious V2 eff ects. Th erefore, more marked in juxtamedullary neph- densa, and collecting-duct principal and the relative contributions of V 2 and V1a rons, may be responsible for functional ␣ -intercalated cells. 13,14 Th e localization receptors to, and potential usefulness of and structural diff erences between super- 18 and function of V1b receptors in the kid- V2 and V 1a receptor antagonists for the fi cial and deep nephrons. Urine-con- ney, possibly in the inner medullary col- treatment of CKD remain ill-defi ned. centrating activity and GFR (or renal lecting duct, are not well characterized. Strong experimental evidence supports blood fl ow) are also correlated in healthy Although RWJ-676070, the compound the hypothesis that the V 2 -mediated human volunteers during low and high 1 19 used by Perico et al.
Load more

Recommended publications
  • MASTER THESIS Reprogramming Human Gastrointestinal Stem Cells
    MASTER THESIS Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Engineering at the University of Applied Sciences Technikum Wien - Degree Program Tissue Engineering and Regenerative Medicine Reprogramming human gastrointestinal stem cells into insulin-secreting cells: developing a cell therapy for diabetes By: Christoph Pertl, BSc Student Number: 01306559 Supervisor 1: Qiao Joe Zhou, Ph.D. Supervisor 2: Dr. rer. nat. Elisabeth Simboeck Vienna, 15/12/2019 Declaration of Authenticity “As author and creator of this work to hand, I confirm with my signature knowledge of the relevant copyright regulations governed by higher education acts (for example see §§ 21, 42f and 57 UrhG (Austrian copyright law) as amended as well as § 14 of the Statute on Studies Act Provisions / Examination Regulations of the UAS Technikum Wien). In particular I declare that I have made use of third-party content correctly, regardless what form it may have, and I am aware of any consequences I may face on the part of the degree program director if there should be evidence of missing autonomy and independence or evidence of any intent to fraudulently achieve a pass mark for this work (see § 14 para. 1 Statute on Studies Act Provisions / Examination Regulations of the UAS Technikum Wien). I further declare that up to this date I have not published the work to hand nor have I presented it to another examination board in the same or similar form. I affirm that the version submitted matches the version in the upload tool.” Place, Date Signature 2 Kurzfassung Eine erfolgreiche Behandlung von Typ 1 Diabetes benötigt das Regenerieren verlorener insulinproduzierender Zellen und das Umgehen der Autoimmunreaktion.
    [Show full text]
  • Puromycin Selective Antibiotic for the Pac Gene Catalog # Ant-Pr-1, Ant-Pr-5 for Research Use Only Version # 13A25-MM
    Puromycin Selective antibiotic for the pac gene Catalog # ant-pr-1, ant-pr-5 For research use only Version # 13A25-MM PRodUCt INFoRmAtIoN ReSIStANCe to PURomYCIN Content: The pac gene encoding a Puromycin N-acetyl-tranferase (PAC) has been isolated Puromycin hydrochloride is supplied as 1ml tubes of a 10 mg/ml solution in from a Streptomyces producing strain 1,2 . It is located in a region of the pur HEPES buffer (100% active product), filtered to sterility for customer cluster linked to the other genes d etermining the puromycin biosynthetic convenience, and cell culture tested. pathway. - ant-pr-1: 10 x 1 ml at 10 mg/ml (100 mg) The expression of pac gene confers puromycin resistance to transfected - ant-pr-5: 50 x 1 ml at 10 mg/ml (500 mg) mammalians cells 3 expressing it. In some particular conditions puromycin could also be used for selection of E. coli strains transformed with plasmids Storage and stability: carrying the pac gene. Puromycin is shipped at room temperature. Upon receipt it should be stored at 4°C or -20°C. Puromycin is stable for two years at -20°C, two years at 4°C, and 3 months at CoNdItIoNS oF SeLeCtIoN room temperature. Avoid repeated freeze-thaw cycles. Puromycin is poorly active on E. coli but is particularly useful in experiments conducted with mammalian cells. It can be used as an alternative to Quality control Neomycin system for transfection experiments. Purity controlled by HPLC: >95% Activity controlled by bioassays on bacteria and mammalian cell lines. mammalian cells The working concentrations of puromycin for mammalian cell lines range SPeCIAL hANdLING from 1 to 10 µg/ml.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • HDAC Inhibition Enhances the in Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
    Published OnlineFirst June 21, 2019; DOI: 10.1158/1078-0432.CCR-18-3382 Translational Cancer Mechanisms and Therapy Clinical Cancer Research HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma Fernanda Faiao-Flores~ 1, Michael F. Emmons1, Michael A. Durante2, Fumi Kinose3, Biswarup Saha1, Bin Fang4, John M. Koomen4, Srikumar P. Chellappan1, Silvya Stuchi Maria-Engler5, Uwe Rix3, Jonathan D. Licht6, J. William Harbour2, and Keiran S.M. Smalley1 Abstract Purpose: The clinical use of MEK inhibitors in uveal mel- expression, particularly the endothelin B receptor, and this anoma is limited by the rapid acquisition of resistance. This contributed to therapeutic escape through ET-3–mediated study has used multiomics approaches and drug screens to YAP signaling. A screen of 289 clinical grade compounds identify the pan-HDAC inhibitor panobinostat as an effective identified HDAC inhibitors as potential candidates that sup- strategy to limit MEK inhibitor resistance. pressed the adaptive YAP and AKT signaling that followed Experimental Design: Mass spectrometry–based proteo- MEK inhibition. In vivo, the MEK-HDAC inhibitor combina- mics and RNA-Seq were used to identify the signaling path- tion outperformed either agent alone, leading to a long-term ways involved in the escape of uveal melanoma cells from decrease of tumor growth in both subcutaneous and liver MEK inhibitor therapy. Mechanistic studies were performed to metastasis models and the suppression of adaptive PI3K/AKT evaluate the escape pathways identified, and the efficacy of the and YAP signaling. MEK-HDAC inhibitor combination was demonstrated in mul- Conclusions: Together, our studies have identified GPCR- tiple in vivo models of uveal melanoma.
    [Show full text]
  • Liraglutide Treatment Ameliorates Neurotoxicity Induced by Stable Silencing of Pin1
    International Journal of Molecular Sciences Article Liraglutide Treatment Ameliorates Neurotoxicity Induced by Stable Silencing of Pin1 Marzia Bianchi 1, Valentina D’Oria 2, Maria Rita Braghini 3, Stefania Petrini 2 and Melania Manco 1,* 1 Research Area for Multi-factorial Diseases, Obesity and Diabetes, Bambino Gesù Children’s Research Hospital, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), viale di San Paolo 15, 00146 Rome, Italy; [email protected] 2 Confocal Microscopy Core Facility, Research Laboratories, Bambino Gesu’ Children’s Research Hospital, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), viale di San Paolo 15, 00146 Rome, Italy; [email protected] (V.D.); [email protected] (S.P.) 3 Molecular Genetics of Complex Phenotypes Research Unit, Bambino Gesù Children’s Research Hospital, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), viale di San Paolo 15, 00146 Rome, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-06-6859-2649 Received: 30 September 2019; Accepted: 11 October 2019; Published: 12 October 2019 Abstract: Post-translational modulation of peptidylprolyl isomerase Pin1 might link impaired glucose metabolism and neurodegeneration, being Pin1 effectors target for the glucagon-Like-Peptide1 analog liraglutide. We tested the hypotheses in Pin1 silenced cells (SH-SY5Y) treated with 2-deoxy-d-glucose (2DG) and methylglyoxal (MG), stressors causing altered glucose trafficking, glucotoxicity and protein glycation. Rescue by liraglutide was investigated. Pin1 silencing caused increased levels of reactive oxygen species, upregulated energy metabolism as suggested by raised levels of total ATP content and mRNA of SIRT1, PGC1α, NRF1; enhanced mitochondrial fission events as supported by raised protein expression of FIS1 and DRP1.
    [Show full text]
  • Antiproteinuric Effect of an Endothelin-1 Receptor Antagonist in Puromycin Aminonucleoside-Induced Nephrosis in Rat
    Basic Science Investigation | Articles Antiproteinuric effect of an endothelin-1 receptor antagonist in puromycin aminonucleoside-induced nephrosis in rat Jiro Kino1, Shoji Tsuji1, Tetsuya Kitao1, Yuko Akagawa1, Sohsaku Yamanouchi1, Takahisa Kimata1 and Kazunari Kaneko BACKGROUND: The pathogenesis of idiopathic nephrotic B7-1) or c-mip has recently attracted attention for its syndrome (INS) remains unclear, although recent studies relationship with INS pathogenesis (3–5). suggest endothelin 1 (ET-1) and CD80 of podocytes are Endothelin (ET), which has a potent vasoconstrictor effect, involved. We investigated the potential of antagonist to ET-1 was shown to be expressed not only in endothelium but also receptor type A (ETRA) as therapeutic agent through the in podocytes, and the potential for ET to cause structural suppression of CD80 in a rat model of INS. changes of podocytes leading to proteinuria has been reported METHODS: Puromycin aminonucleoside (PAN) was injected (6–8). Therefore, the possibility of using a therapeutic drug to Wister rats to induce proteinuria: some were treated with that is an ET receptor type A (ETRA) antagonist has gained ETRA antagonist and others were treated with 0.5% prominence. In fact, it has been reported to reduce methylcellulose. Blood and tissue samples were collected. proteinuria and prevent glomerulosclerosis (9–11), although Quantitative PCR was used to determine the expression of its mechanisms of action remain to be clarified. Toll-like receptor-3 (TLR-3), nuclear factor-κB (NF-κB), CD80, Taken together, we wonder whether ETRA antagonist talin, ETRA, and ET-1 in the kidney. To confirm the level of (ambrisentan) ameliorates proteinuria in INS through CD80 protein expression, immunofluorescence staining and modification of podocyte-related molecules including CD80.
    [Show full text]
  • A Study of the SERCA-Phospholamban Regulatory Interaction Using Time-Resolved Fluorescence
    A Study of the SERCA-Phospholamban Regulatory Interaction Using Time-Resolved Fluorescence A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Daniel Richard Stroik IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY David D. Thomas, Advisor August 2018 Daniel Richard Stroik 2018 © Acknowledgements It is a difficult task to thank everyone in a laboratory as expansive and layered as the DDT group; but I will begin by thanking my advisor, Dr. David Thomas. I always appreciated his willingness to help others without prejudice or profit, and it is no surprise that this has afforded him many friends and allies over the years. He has always pushed me and for this I am grateful. My time here has made me excited for a future career in science and ready to go after any discovery. I would like to thank my committee Dr. John Lipscomb, Dr. Wendy Gordon, and Dr. Sivaraj Sivaramakrishnan. They have provided me with guidance and support, and I have always found useful knowledge and inspiration through our interactions. Because of the directions that my thesis project took, I worked very closely with Dr. Razvan Cornea and Dr. Mike Autry. I have always enjoyed their feedback and am very lucky to be surrounded by positive role models. I aspire to be as strong a writer and as clear-thinking a scientist as Razvan. Mike has always been supportive and is one of the most knowledgeable scientists I have ever met. The time he takes to train his students impresses me and he is truly a man of integrity.
    [Show full text]
  • Insulin Action/Molecular Metabolism
    INSULIN ACTION—ADIPOCYTECATEGORY BIOLOGY 1692-P 1694-P Stress in Beta Cells Obtained with Laser Capture Microdissection Biopsy-Proven Insulitis of Clinical Islet Transplantation Is Not from Cadaver Pancreases of Brain Dead Donors Reversed by Steroid Therapy AREF EBRAHIMI, MIN-HO JUNG, JONATHAN M. DREYFUSS, HUI PAN, DENNIS ANNA LAM, BEHRUZ RAHIMI, SHARLEEN IMES, KIM SOLEZ, JAMES SHAPIRO, C. SGROI, SUSAN BONNER-WEIR, GORDON C. WEIR, Boston, MA PETER A. SENIOR, Edmonton, AB, Canada Brain death of pancreas donors is thought to lead to the expression of Gradual decline in islet function remains a challenge in clinical islet infl ammatory, stress and apoptotic pathways in isolated islets resulting in transplantation (CIT), but acute graft loss is relatively uncommon. Here we poor clinical outcomes. To test this hypothesis we obtained cadaveric pan- describe a case of acute decline in graft function with histology suggesting creases from brain dead pancreatic donors (n=7, mean age 5011) and normal an immune mechanism. A 49 year old female (BMI 24.4 kg/m2, insulin 0.3 pancreatic tissue obtained at surgery done for pancreatic neoplasms (n=7, U/kg) with type 1 diabetes for 37 years underwent two CIT (6071 and 6827 age 699). Frozen sections were subjected to laser capture microdissection islet equivalents/kg) following alemtuzumab induction with tacrolimus (TAC, to obtain beta-cell rich islet tissue, from which extracted RNA was analyzed mean 8 ug/L) and mycophenolate mofetil for maintenance. Initial engraft- with Affymetrix arrays. Gene expression of the two groups was evaluated ment was reasonable (β2 score of 12 at 1 week), but β2 score gradually with principle component analysis (PCA), and differential expression anal- declined (Figure 1) rising to 19 after the second CIT.
    [Show full text]
  • Suppression of Protein Synthesis with Puromycin and of RNA Synthesis with Actino- Mycin
    1112 MICROBIOLOGY: WAGNER AND HUANG PROC. N. A. S. 19 Brock, T. D., Science, 129, 960 (1959). 20 Clamp, J. R., and L. Hough, Biochem. J., 94, 17 (1965). 21 Vidaver, A. M. K., Ph.D. dissertation, Indiana University, Bloomington (1965). 22 Stahl, E., and U. Kaltenbach, J. Chromatog., 5, 351 (1961). 23Falcone, G., and W. J. Nickerson, Science, 124, 272 (1956). 24 Nickerson, W. J., and G. Falcone, Science, 124, 318 (1956). 25Ibid., p. 722. 26 Lampen, J. O., in Function and Structure in Microorganisms (Cambridge: Society for General Microbiology, 1965), p. 120. REVERSIBLE INHIBITION OF INTERFERON SYNTHESIS BY PUROMYCIN: EVIDENCE FOR AN INTERFERON-SPECIFIC MESSENGER RNA * BY ROBERT R. WAGNER AND ALICE S. HUANG DEPARTMENT OF MICROBIOLOGY, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, BALTIMORE Communicated by W. Barry Wood, Jr., August 24, 1965 The capacity to synthesize interferon appears to be a latent cellular function which is induced by viral infection or other stimuli. The sequence of events can be conveniently studied in suspended cultures of Krebs-2 mouse ascites cells infected with Newcastle disease virus (NDV). Interferon synthesis in this model system begins 3-4 hr after infection and reaches maximal levels within 20 hr after viral infection.'1 2 Previous studies have shown that interferon formation requires unimpaired cellular RNA synthesis during the first 4 hr after viral induction." 2 Following this time, interferon continues to be formed even if RNA synthesis is inhibited by actinomycin. The present experiments provide further support for the hypothesis that a virus can switch on the cellular interferon gene by inducing the transcription of a messenger RNA that specifies the synthesis of the interferon protein.
    [Show full text]
  • Qt38n028mr Nosplash A3e1d84
    ! ""! ACKNOWLEDGEMENTS I dedicate this thesis to my parents who inspired me to become a scientist through invigorating scientific discussions at the dinner table even when I was too young to understand what the hippocampus was. They also prepared me for the ups and downs of science and supported me through all of these experiences. I would like to thank my advisor Dr. Elizabeth Blackburn and my thesis committee members Dr. Eric Verdin, and Dr. Emmanuelle Passegue. Liz created a nurturing and supportive environment for me to explore my own ideas, while at the same time teaching me how to love science, test my questions, and of course provide endless ways to think about telomeres and telomerase. Eric and Emmanuelle both gave specific critical advice about the proper experiments for T cells and both volunteered their lab members for further critical advice. I always felt inspired with a sense of direction after thesis committee meetings. The Blackburn lab is full of smart and dedicated scientists whom I am thankful for their support. Specifically Dr. Shang Li and Dr. Brad Stohr for their stimulating scientific debates and “arguments.” Dr. Jue Lin, Dana Smith, Kyle Lapham, Dr. Tet Matsuguchi, and Kyle Jay for their friendships and discussions about what my data could possibly mean. Dr. Eva Samal for teaching me molecular biology techniques and putting up with my late night lab exercises. Beth Cimini for her expertise with microscopy, FACs, singing, and most of all for being a caring and supportive friend. Finally, I would like to thank Dr. Imke Listerman, my scientific partner for most of the breast cancer experiments.
    [Show full text]
  • Puromycin Ready Made Solution (P9620)
    Puromycin Ready Made Solution from Streptomyces alboniger Catalog Number P9620 Storage Temperature -20 °C CAS RN: 53-79-2 (free base) This product is a ready-to-use 10 mg/ml solution (as Synonyms: (S)-3¢-[[2-amino-3-(4-methoxyphenyl)- puromycin dihydrochloride) in water, sterile filtered 1-oxopropyl]-amino]-3¢-deoxy-N,N-dimethyl-adenosine, using a 0.2 mm filter. It is tested on HeLa cells for cell Stylomycin growth arrest and selection of cells after transfection of the pac resistance gene. Hela cells were found to be resistant to a concentration of 0.1-0.3 mg/ml and sensitive to a concentration in the range of 1-10 mg/ml. For selection of pac-containing colonies after transfection it is better to use the antibiotic supplemented in the cell medium 2 days after transfection, in the range of 1-6 mg/ml. Colonies will appear 7-10 days after transfection. The optimal working concentration of puromycin varies between cell lines. Usually, the working concentration Molecular formula: C22H29N7O5 (free base) Molecular weight: 471.51 for eukaryote cell culture is 1-10 mg/ml. Product Description Precautions and Disclaimer Puromycin belongs to the amino-nucleoside family of This product is for R&D use only, not for drug, antibiotics and is isolated from Streptomyces alboniger. household, or other uses. Please consult the Material Since the partial structure of this antibiotic showed it to Safety Data Sheet for information regarding hazards be a purine derivative, puromycin was assigned as its and safe handling practices. generic name. Storage/Stability Puromycin is a broad spectrum antibiotic and Store the product at –20 °C.
    [Show full text]
  • Insulin Resistance Causes Inflammation in Adipose Tissue
    Insulin resistance causes inflammation in adipose tissue Mitsugu Shimobayashi, … , Ralph Peterli, Michael N. Hall J Clin Invest. 2018;128(4):1538-1550. https://doi.org/10.1172/JCI96139. Research Article Inflammation Metabolism Obesity is a major risk factor for insulin resistance and type 2 diabetes. In adipose tissue, obesity-mediated insulin resistance correlates with the accumulation of proinflammatory macrophages and inflammation. However, the causal relationship of these events is unclear. Here, we report that obesity-induced insulin resistance in mice precedes macrophage accumulation and inflammation in adipose tissue. Using a mouse model that combines genetically induced, adipose-specific insulin resistance (mTORC2-knockout) and diet-induced obesity, we found that insulin resistance causes local accumulation of proinflammatory macrophages. Mechanistically, insulin resistance in adipocytes results in production of the chemokine monocyte chemoattractant protein 1 (MCP1), which recruits monocytes and activates proinflammatory macrophages. Finally, insulin resistance (high homeostatic model assessment of insulin resistance [HOMA-IR]) correlated with reduced insulin/mTORC2 signaling and elevated MCP1 production in visceral adipose tissue from obese human subjects. Our findings suggest that insulin resistance in adipose tissue leads to inflammation rather than vice versa. Find the latest version: http://jci.me/96139/pdf RESEARCH ARTICLE The Journal of Clinical Investigation Insulin resistance causes inflammation in adipose tissue Mitsugu Shimobayashi,1 Verena Albert,1 Bettina Woelnerhanssen,2 Irina C. Frei,1 Diana Weissenberger,1 Anne Christin Meyer-Gerspach,2 Nicolas Clement,3 Suzette Moes,1 Marco Colombi,1 Jerome A. Meier,1 Marta M. Swierczynska,1 Paul Jenö,1 Christoph Beglinger,2 Ralph Peterli,3 and Michael N. Hall1 1Biozentrum, University of Basel, Basel, Switzerland.
    [Show full text]